Universal Access and Affordable Medicines
Our campaign promotes transparency, accountability and the public interest in the field of pharmaceuticals. Our evidence-based advocacy aims to guarantee better and affordable medicines for Europe by questioning and reforming the current pharmaceutical business model and calling for better access to medicines for all.
About our work on access to medicines
Transparency is needed to reap the full benefits of the EU’s investment in its Vaccines Strategy, say health NGOs
Ahead of the upcoming hearing on the #EUVaccinesStrategy, public health organisations, not-for-profit healthcare insurers, healthcare professionals call for more transparency and fair return on public investment in vaccines
Joint statement supported by EPHA following MEPs’ vote on medicines shortages report
new recommendations from civil society on how public interest and public health should prevail as leading priorities when regulating the pharmaceutical sector.
Analysis & Opinion
The coronavirus disease offers pharma companies the possibility for public trust in them to be restored. It remains to be seen if they will grasp this chance.
Get monthly updates on key public health issues!
Time for a new deal
14 November 2019
4th EPHA Universal Access and Affordable Medicines Forum. Challenging the status quo on medicines policy.
Putting health first
3 June 2019
Trailblazers, routes to better and affordable medicines by 2025
20 November 2018
How good are our medicines?
3 October 2018
Game changers for better and affordable medicines in Europe
21 November 2017
At the European Health Forum Gastein
Do you have a question?
Meet our Universal Access and Affordable Medicines Policy Lead.
+32 2 233 3886